单次与三次透明质酸治疗膝骨关节炎 (DR-HAKOA)
单次与三次透明质酸注射治疗膝骨关节炎的效果与安全性
The goal of this clinical trial is to directly compare two hyaluronic acid injection protocols in adults with knee osteoarthritis: a single intra-articular injection of Innoryos 2.5% (Single-Shot) and a three-week injection series of Innoryos 2.2% (Triple-Shot). The study aims to determine whether the single injection provides comparable safety, pain relief, and improvement in knee function to the triple-injection protocol.
The main questions are:
- How do the single-shot and triple-shot protocols compare in terms of pain reduction and functional improvement?
- How do their safety and tolerability profiles compare?
- What medical problems occur with each protocol? Participants (n = 46) will receive either the single 4.8 ml injection or three weekly 2 ml injections. They will attend clinic visits at baseline, Week 6, Week 12, and Week 24 for assessments including WOMAC score, 7-day pain diary, functional and strength tests, and MRI scans of the knee.
This single-center, partially blinded, randomized study will provide a direct comparison of the two HA injection protocols, assessing whether the single-shot approach is as safe and effective as the triple-shot regimen, while potentially offering a more convenient, patient-friendly treatment.
研究概览
地位
条件
详细说明
Background:
Knee osteoarthritis (gonarthrosis) is a prevalent degenerative joint disease characterized by cartilage loss, joint pain, stiffness, and functional impairment, which significantly affects mobility and quality of life. Intra-articular injections of hyaluronic acid (HA) are a well-established conservative therapy to reduce pain, improve function, and potentially delay surgical interventions. Various HA formulations and injection protocols exist, differing in molecular weight, concentration, and dosing schedules. Optimizing treatment in terms of efficacy, safety, patient convenience, and cost-effectiveness remains a key clinical goal.
Objective:
This study aims to compare the safety, tolerability, and efficacy of a single intra-articular injection of Innoryos 2.5% (Single-Shot) with a standard three-week injection regimen of Innoryos 2.2% (Triple-Shot) in adults with moderate to severe knee osteoarthritis. The primary focus is on safety and pain reduction, with secondary outcomes including functional improvement, leg muscle strength, and structural assessment of the knee joint via MRI.
Study Design:
This is a single-center, randomized, partially blinded, parallel-group clinical intervention study including 46 participants. Patients are randomized using block randomization stratified by baseline WOMAC total score to ensure balanced distribution of baseline pain and functional impairment. Patients and treating physicians are aware of treatment allocation, while all personnel performing functional tests, MRI assessments, data entry, and statistical analyses are blinded to minimize bias.
Participants:
Adults aged 40-70 years with radiographically confirmed moderate to severe knee osteoarthritis, experiencing knee pain for at least three months and on at least 50% of days in the prior month. Key exclusion criteria include grade 4 osteoarthritis, non-osteoarthritic knee pain, other rheumatic diseases, recent HA or corticosteroid injections, recent trauma or surgery, coagulopathies, autoimmune disorders, pregnancy or lactation, and contraindications for MRI.
Interventions:
- Single-Shot Group: One intra-articular injection of Innoryos 2.5% (4.8 ml)
- Triple-Shot Group: Three intra-articular injections of Innoryos 2.2% (2 ml each) at weekly intervals
Outcomes:
The primary outcome is total WOMAC score. Secondary outcomes include WOMAC subscales, VAS pain diary, functional performance, leg muscle strength, MRI-detected structural changes, and safety/tolerability parameters.
Assessments:
Participants are assessed at baseline, Week 6, Week 12, and Week 24.
- WOMAC questionnaire (baseline, Week 6, Week 12, and Week 24): Pain, stiffness, and functional limitation
- Pain diary (VAS) (baseline, Week 6, Week 12, and Week 24): Daily for 7 days at each assessment (~1 min/day)
- Functional and strength tests (baseline, Week 6, Week 12): Chair Stand Test, Timed Up and Go Test, isokinetic leg press (~30 min per session)
- MRI (baseline, Week 6, Week 12): Baseline and Week 12 for structural assessment (~90 min including functional tests)
- Safety monitoring: Adverse events, medication use, compliance, drop-outs
Significance:
This study provides high-quality evidence for the direct comparison of single-shot versus triple-shot HA injection protocols in knee osteoarthritis. By using stratified randomization based on baseline WOMAC total score and blinded assessment of outcomes, the trial ensures unbiased evaluation. Demonstration of comparable safety and efficacy of the single-shot regimen could offer a more convenient, patient-friendly, and potentially safer therapeutic option, optimizing conservative management for patients with knee osteoarthritis.
intra-articular injection of Innoryos 2.5% (Single-Shot) with a standard three-week injection regimen of Innoryos 2.2% (Triple-Shot) in adults with moderate to severe knee osteoarthritis. The primary focus is on safety and pain reduction, with secondary outcomes including functional improvement, leg muscle strength, and structural assessment of the knee joint via MRI.
Study Design:
This is a single-center, randomized, partially blinded, parallel-group clinical intervention study including 46 participants. Patients are randomized using block randomization stratified by baseline WOMAC total score to ensure balanced distribution of baseline pain and functional impairment. Patients and treating physicians are aware of treatment allocation, while all personnel performing functional tests, MRI assessments, data entry, and statistical analyses are blinded to minimize bias.
Participants:
Adults aged 40-70 years with radiographically confirmed moderate to severe knee osteoarthritis, experiencing knee pain for at least three months and on at least 50% of days in the prior month. Key exclusion criteria include grade 4 osteoarthritis, non-osteoarthritic knee pain, other rheumatic diseases, recent HA or corticosteroid injections, recent trauma or surgery, coagulopathies, autoimmune disorders, pregnancy or lactation, and contraindications for MRI.
研究类型
注册 (实际的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习地点
-
-
-
Erlangen、德国、91052
- Institute of Radiology, University Hospital Erlangen
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adults aged 40-70 years
- Radiographically confirmed moderate to severe knee osteoarthritis
- Knee pain for ≥3 months
- Pain on ≥50% of days in past 30 days
- Able to provide informed consent
Exclusion Criteria:
- Grade 4 osteoarthritis (full-thickness cartilage loss)
- Non-osteoarthritic knee pain
- Other rheumatic diseases (e.g., rheumatoid arthritis, fibromyalgia)
- HA injection <6 months or corticosteroid injection <3 months in target knee
- Recent trauma or surgery of affected knee (<6 months)
- Coagulopathy or bleeding disorder
- Autoimmune or relevant systemic disease
- Dermatologic infection at injection site
- Pregnancy or lactation
- Opioid or oral corticosteroid use
- Contraindications to MRI (pacemaker, intracorporeal metal, claustrophobia)
- Expected absence during study period or noncompliance
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Three intra-articular HA injections
Three intra-articular injections of Innoryos 2.2% (2 ml each) in the knee joint at weekly intervals |
Therapy with intra-articular injections of hyaluronic acid (HA). Three intra-articular injections of Innoryos 2.2% (2 ml per injection) administered into the affected knee joint at weekly intervals. |
|
实验性的:One intra-articular HA injection
One intra-articular injection of Innoryos 2.5% (4.8 ml) in the knee joint |
Therapy with a single intra-articular injection of hyaluronic acid (HA). One intra-articular injection of Innoryos 2.5% (4.8 ml per injection) administered into the affected knee joint at weekly intervals. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
WOMAC questionnaire total score
大体时间:At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
Total score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing overall pain, stiffness, and physical function of the knee joint |
At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
WOMAC questionnaire pain subscore
大体时间:At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
Pain subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing pain of the knee joint |
At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
|
WOMAC questionnaire stiffness subscore
大体时间:At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
Stiffness subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing stiffness of the knee joint |
At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
|
WOMAC questionnaire physical function subscore
大体时间:At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
Physical function subscore of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), assessing pain of the knee joint |
At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
|
7-day pain assessment using visual analog scale (VAS)
大体时间:At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
Participants will record their knee pain daily using a Visual Analog Scale (VAS) as part of a 7-day pain diary at each assessment period. The VAS is a straight 100 mm line, anchored by "no pain" at 0 mm and "worst imaginable pain" at 100 mm. Participants indicate their current knee pain intensity each day by marking a point on the line that best represents their pain. The diary is completed for seven consecutive days to capture fluctuations in pain intensity during daily activities. The daily VAS scores are recorded and later averaged to calculate a weekly mean pain score. |
At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
|
Maximum isokinetic leg extension strength
大体时间:At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
Participants' leg muscle strength and functional performance are assessed using an isokinetic leg press (Physiomed, Laipersdorf, Germany). Before testing, participants complete a 5-minute warm-up on a cross-trainer to prepare the muscles and reduce injury risk. Following the warm-up, two maximal test sessions are conducted, each consisting of 6 repetitions at a velocity of 0.6 meters per second (m/s). During each attempt, participants perform the leg press extension movement with maximal effort. The highest peak force achieved during the extension in each session is recorded and used for analysis. |
At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
|
30-Second Chair Stand Test (30s CST) - Assessment of Lower Limb Function:
大体时间:At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
The 30-Second Chair Stand Test measures lower body strength, endurance, and functional mobility. Participants sit on a standard chair with arms crossed over the chest. When instructed, they stand up fully and sit back down repeatedly for 30 seconds. The total number of full stands completed within 30 seconds is recorded. A higher number of repetitions indicates better lower limb strength and functional performance. |
At baseline, at 6 weeks, at 12 weeks, at 24 weeks
|
|
Knee MRI and T2 Mapping - Assessment of Joint Structures
大体时间:At baseline, at 12 weeks, at 24 weeks
|
Magnetic Resonance Imaging (MRI) is used to assess structural changes in the knee joint and evaluate the integrity of cartilage and other joint tissues. Participants undergo a non-invasive, radiation-free MRI scan of the affected knee at baseline and 12 weeks after treatment. The MRI protocol includes high-resolution imaging of joint structures, such as cartilage, menisci, ligaments, and subchondral bone. Additionally, T2 mapping is performed to quantify the T2 relaxation time of articular cartilage, which reflects the water content and collagen organization. Areas of increased T2 values indicate cartilage degeneration or changes in cartilage composition, while decreases or stabilization suggest maintenance or improvement of cartilage health. |
At baseline, at 12 weeks, at 24 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Compliance and Drop-Out
大体时间:up to 24 weeks
|
Compliance refers to the degree to which participants adhere to the assigned injection protocol and scheduled study visits. For the Single-Shot group, compliance is assessed by confirming that participants receive the planned single 4.8 ml injection at baseline. For the Triple-Shot group, compliance is assessed by verifying that participants receive all three weekly 2 ml injections according to the study schedule. Compliance is documented in the study records and serves as a measure of treatment adherence and feasibility of the respective protocols. Drop-Out refers to participants who withdraw from the study before completion or fail to attend follow-up assessments at the scheduled time points (baseline, Week 6, Week 12, Week 24). Reasons for drop-out, including adverse events, personal choice, or loss to follow-up, are recorded. Drop-out rates are analyzed as an endpoint to evaluate the acceptability, tolerability, and practicality of each |
up to 24 weeks
|
|
Medication Use - Analgesic Tracking
大体时间:Up to 24 weeks
|
Participants record their use of pain medications during the 7-day pain diary period, which accompanies the daily Numeric Rating Scale (NRS) for knee pain. Each day, participants document: The type of pain medication taken The dosage The timing of administration |
Up to 24 weeks
|
|
Adverse Effects - Safety Endpoint
大体时间:Up to 24 weeks
|
Adverse effects are monitored to assess the safety and tolerability of the hyaluronic acid injection protocols. Participants are instructed to report any adverse events or reactions following the injections. Specifically: Short-term monitoring: Participants record any adverse effects daily for 7 days after each injection. This includes local reactions at the injection site (e.g., pain, swelling, redness) as well as any systemic symptoms (e.g., fatigue, fever). Long-term monitoring: Adverse effects are also tracked throughout the entire study duration. All reported adverse events are documented, classified, and analyzed according to severity, duration, and possible relation to the treatment. |
Up to 24 weeks
|
合作者和调查者
调查人员
- 首席研究员:Simon von Stengel, PhD、Institute of Radiology, University Hospital Erlangen, Germany
出版物和有用的链接
一般刊物
- Kast S, Kemmler W, Roemer FW, Kohl M, Culvenor AG, Mobasheri A, Uder M, von Stengel S. Effectiveness of whole-body electromyostimulation on knee pain and physical function in knee osteoarthritis: a randomized controlled trial. Sci Rep. 2024 Sep 6;14(1):20804. doi: 10.1038/s41598-024-71552-7.
- Roemer FW, Kast S, Kemmler W, Collins JE, Engelke K, Guermazi A, Uder M, von Stengel S. Structural effects of whole body electromyostimulation on knee osteoarthritis: the EMSOAT Study. Skeletal Radiol. 2025 Nov;54(11):2579-2588. doi: 10.1007/s00256-025-04984-5. Epub 2025 Jul 22.
- Hofweber, L., von Stengel, S., Nürnberger, J., & Kemmler, W. (2024). Effectiveness and safety of the hyaluronic acid INNORYOS 2.2% in patients with early to advanced knee osteoarthritis. A prospective non-interventional randomized clinical trial.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 25-275_1-Bm
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data (IPD) from this study will not be shared publicly in order to comply with data protection regulations in Germany (GDPR) and the study's data protection consent. Only aggregated and anonymized results will be reported in publications or study summaries. No personal identifiers, contact information, or sensitive participant data will be disclosed.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.